VERTEX PHARMACEUTICALS INC (VX1.DE) Fundamental Analysis & Valuation

FRA:VX1 • US92532F1003

415.8 EUR
-10.8 (-2.53%)
Last: Mar 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This VX1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

VX1 gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. VX1 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. VX1 is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, VX1 could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

7

1. VX1.DE Profitability Analysis

1.1 Basic Checks

  • VX1 had positive earnings in the past year.
  • VX1 had a positive operating cash flow in the past year.
  • VX1 had positive earnings in 4 of the past 5 years.
  • Of the past 5 years VX1 4 years had a positive operating cash flow.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • VX1 has a Return On Assets of 15.42%. This is amongst the best in the industry. VX1 outperforms 91.57% of its industry peers.
  • The Return On Equity of VX1 (21.18%) is better than 89.16% of its industry peers.
  • VX1 has a better Return On Invested Capital (15.14%) than 92.77% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for VX1 is above the industry average of 12.16%.
Industry RankSector Rank
ROA 15.42%
ROE 21.18%
ROIC 15.14%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • VX1 has a better Profit Margin (32.94%) than 91.57% of its industry peers.
  • In the last couple of years the Profit Margin of VX1 has declined.
  • Looking at the Operating Margin, with a value of 39.04%, VX1 belongs to the top of the industry, outperforming 91.57% of the companies in the same industry.
  • VX1's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 86.24%, VX1 is in the better half of the industry, outperforming 75.90% of the companies in the same industry.
  • In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
Industry RankSector Rank
OM 39.04%
PM (TTM) 32.94%
GM 86.24%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. VX1.DE Health Analysis

2.1 Basic Checks

  • VX1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for VX1 has been reduced compared to 1 year ago.
  • The number of shares outstanding for VX1 has been reduced compared to 5 years ago.
  • The debt/assets ratio for VX1 has been reduced compared to a year ago.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • An Altman-Z score of 12.64 indicates that VX1 is not in any danger for bankruptcy at the moment.
  • VX1 has a better Altman-Z score (12.64) than 91.57% of its industry peers.
  • VX1 has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.03, VX1 belongs to the best of the industry, outperforming 97.59% of the companies in the same industry.
  • A Debt/Equity ratio of 0.01 indicates that VX1 is not too dependend on debt financing.
  • VX1 has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. VX1 outperforms 89.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Altman-Z 12.64
ROIC/WACC1.71
WACC8.85%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • VX1 has a Current Ratio of 2.90. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
  • VX1 has a Current ratio of 2.90. This is comparable to the rest of the industry: VX1 outperforms 59.04% of its industry peers.
  • VX1 has a Quick Ratio of 2.46. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
  • VX1 has a Quick ratio of 2.46. This is in the better half of the industry: VX1 outperforms 60.24% of its industry peers.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.46
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. VX1.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 6248.28% over the past year.
  • VX1 shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.27% yearly.
  • The Revenue has grown by 8.90% in the past year. This is quite good.
  • Measured over the past years, VX1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.10% on average per year.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.36% on average over the next years. This is quite good.
  • VX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.31% yearly.
EPS Next Y5.3%
EPS Next 2Y9.43%
EPS Next 3Y10.17%
EPS Next 5Y12.36%
Revenue Next Year8.79%
Revenue Next 2Y9.46%
Revenue Next 3Y10.13%
Revenue Next 5Y10.31%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

4

4. VX1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 26.09, which means the current valuation is very expensive for VX1.
  • Based on the Price/Earnings ratio, VX1 is valued a bit cheaper than the industry average as 77.11% of the companies are valued more expensively.
  • VX1 is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 25.71, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 24.77 indicates a rather expensive valuation of VX1.
  • VX1's Price/Forward Earnings ratio is rather cheap when compared to the industry. VX1 is cheaper than 80.72% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of VX1 to the average of the S&P500 Index (23.82), we can say VX1 is valued inline with the index average.
Industry RankSector Rank
PE 26.09
Fwd PE 24.77
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 77.11% of the companies in the same industry are more expensive than VX1, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of VX1 indicates a somewhat cheap valuation: VX1 is cheaper than 79.52% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 38.19
EV/EBITDA 22.97
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of VX1 may justify a higher PE ratio.
PEG (NY)4.92
PEG (5Y)2.13
EPS Next 2Y9.43%
EPS Next 3Y10.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VX1.DE Dividend Analysis

5.1 Amount

  • No dividends for VX1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VX1.DE Fundamentals: All Metrics, Ratios and Statistics

VERTEX PHARMACEUTICALS INC

FRA:VX1 (3/12/2026, 7:00:00 PM)

415.8

-10.8 (-2.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners97.75%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap105.63B
Revenue(TTM)12.00B
Net Income(TTM)3.95B
Analysts81.03
Price Target461.23 (10.93%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.17%
Min EPS beat(2)-2.79%
Max EPS beat(2)3.12%
EPS beat(4)2
Avg EPS beat(4)-0.85%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)4
Avg EPS beat(8)-64.44%
EPS beat(12)6
Avg EPS beat(12)-43.04%
EPS beat(16)9
Avg EPS beat(16)-31.46%
Revenue beat(2)0
Avg Revenue beat(2)-1.36%
Min Revenue beat(2)-1.51%
Max Revenue beat(2)-1.21%
Revenue beat(4)1
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)0.06%
Revenue beat(8)3
Avg Revenue beat(8)-0.66%
Revenue beat(12)4
Avg Revenue beat(12)-0.75%
Revenue beat(16)6
Avg Revenue beat(16)-0.51%
PT rev (1m)2.72%
PT rev (3m)7.22%
EPS NQ rev (1m)-9.25%
EPS NQ rev (3m)-9.31%
EPS NY rev (1m)-4.91%
EPS NY rev (3m)-4.92%
Revenue NQ rev (1m)-1.94%
Revenue NQ rev (3m)-1.76%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-0.05%
Valuation
Industry RankSector Rank
PE 26.09
Fwd PE 24.77
P/S 10.16
P/FCF 38.19
P/OCF 33.59
P/B 6.53
P/tB 7.11
EV/EBITDA 22.97
EPS(TTM)15.94
EY3.83%
EPS(NY)16.79
Fwd EY4.04%
FCF(TTM)10.89
FCFY2.62%
OCF(TTM)12.38
OCFY2.98%
SpS40.91
BVpS63.63
TBVpS58.48
PEG (NY)4.92
PEG (5Y)2.13
Graham Number151.07
Profitability
Industry RankSector Rank
ROA 15.42%
ROE 21.18%
ROCE 21.51%
ROIC 15.14%
ROICexc 24.16%
ROICexgc 27.17%
OM 39.04%
PM (TTM) 32.94%
GM 86.24%
FCFM 26.61%
ROA(3y)9.65%
ROA(5y)12.94%
ROE(3y)12.83%
ROE(5y)17.11%
ROIC(3y)15.82%
ROIC(5y)17.01%
ROICexc(3y)28.92%
ROICexc(5y)41.25%
ROICexgc(3y)35.7%
ROICexgc(5y)59.25%
ROCE(3y)22.47%
ROCE(5y)24.17%
ROICexgc growth 3Y-36.41%
ROICexgc growth 5Y-24.43%
ROICexc growth 3Y-28.98%
ROICexc growth 5Y-17.32%
OM growth 3Y-7.71%
OM growth 5Y-3.24%
PM growth 3Y-3.97%
PM growth 5Y-5.49%
GM growth 3Y-0.63%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.03
Debt/EBITDA 0.02
Cap/Depr 208.58%
Cap/Sales 3.65%
Interest Coverage 377.85
Cash Conversion 74.18%
Profit Quality 80.79%
Current Ratio 2.9
Quick Ratio 2.46
Altman-Z 12.64
F-Score7
WACC8.85%
ROIC/WACC1.71
Cap/Depr(3y)195.12%
Cap/Depr(5y)182.1%
Cap/Sales(3y)3.56%
Cap/Sales(5y)3.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y5.3%
EPS Next 2Y9.43%
EPS Next 3Y10.17%
EPS Next 5Y12.36%
Revenue 1Y (TTM)8.9%
Revenue growth 3Y10.35%
Revenue growth 5Y14.1%
Sales Q2Q%9.55%
Revenue Next Year8.79%
Revenue Next 2Y9.46%
Revenue Next 3Y10.13%
Revenue Next 5Y10.31%
EBIT growth 1Y6.59%
EBIT growth 3Y1.84%
EBIT growth 5Y10.4%
EBIT Next Year6.57%
EBIT Next 3Y12.66%
EBIT Next 5Y11.43%
FCF growth 1Y426.56%
FCF growth 3Y-6.64%
FCF growth 5Y1.3%
OCF growth 1Y837.19%
OCF growth 3Y-4.2%
OCF growth 5Y2.22%

VERTEX PHARMACEUTICALS INC / VX1.DE FAQ

What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?

ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.


What is the valuation status for VX1 stock?

ChartMill assigns a valuation rating of 4 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.


What is the profitability of VX1 stock?

VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (VX1.DE) is 9 / 10.


What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 5.3% in the next year.